Auto Dealer Valuation Insights

AUGUST 4, 2023

Mercer Capital’s Value Focus: Exploration & Production newsletter provides an overview of the industry through supply and demand analysis, commodity pricing, and public market performance.

Marketability 52

Marketability 52

Auto Dealer Valuation Insights

APRIL 27, 2023

Mercer Capital’s Value Focus: Exploration & Production newsletter provides an overview of the industry through supply and demand analysis, commodity pricing, and public market performance.

Marketability 52

Marketability 52

Benzinga

AUGUST 26, 2022

Open Text Corp (NASDAQ: OTEX ) subsidiary OpenText UK Holding Limited agreed to acquire Micro Focus Intl PLC (NYSE: MFGP ) for 532 pence per share, implying an enterprise value of $6.0 The purchase offer is roughly twice Micro Focus's closing price on August 25 ($3.13) before news of the takeover came to light.

Enterprise Value 97

Enterprise Value 97

Benzinga

APRIL 11, 2024

Janux Therapeutics Inc (NASDAQ: JANX ) shares are trading higher following Wednesday’s reports suggesting the company is considering a possible sale following interest from larger pharmaceutical firms.

52

52

Mckinsey and Company

APRIL 4, 2024

Leaders today confront a raft of complexities. Here’s what will matter most as 2024 evolves—and how CEOs can reckon with ongoing disruption successfully.

Corporate Finance 114

Corporate Finance Finance 114

Law 360 M&A

MAY 17, 2024

Shares of RF Acquisition II, a special-purpose acquisition company targeting the technology sector in Asia, began trading publicly on Friday following the company's $100 million initial public offering.

Technology 52

Technology 52

Auto Dealer Valuation Insights

JANUARY 20, 2023

Mercer Capital’s Value Focus: Exploration & Production newsletter provides an overview of the industry through supply and demand analysis, commodity pricing, and public market performance.

Marketability 52

Marketability 52

Benzinga

MARCH 6, 2023

Adaptimmune Therapeutics plc (NASDAQ: ADAP ) is merging with TCR² Therapeutics Inc (NASDAQ: TCRR ) in an all-stock deal to create a cell therapy company focused on treating solid tumors. The lead clinical franchises for the combined company utilize engineered T-cell therapies targeting MAGE-A4 and mesothelin.

97

97

Law 360 M&A

DECEMBER 6, 2023

Blue Room Acquisition Corp., a special-purpose acquisition company focused on acquiring a financial services business, filed plans Wednesday for a $200 million initial public offering, represented by Ellenoff Grossman & Schole LLP and underwriters counsel Loeb & Loeb LLP.

52

52

Law 360 M&A

MAY 26, 2022

A sports and entertainment focused blank-check firm, whose board of directors includes former NBA star Magic Johnson and a former Disney executive, was among two special-purpose acquisition companies to file initial public offerings Thursday for a combined $350 million.

98

98

Auto Dealer Valuation Insights

AUGUST 19, 2022

Mercer Capital’s Value Focus: Exploration & Production newsletter provides an overview of the industry through supply and demand analysis, commodity pricing, and public market performance.

Marketability 52

Marketability 52

Benzinga

MARCH 6, 2024

Both companies’ boards have approved the Merger Agreement. YOOV is a business artificial intelligence (AI) and automation platform to optimize various aspects of business operations. Under the merger agreement, Aptorum’s subsidiary will merge into YOOV.

59

59

LaPorte

FEBRUARY 23, 2024

The post Beyond M&A: Hospitals turn to joint ventures for growth, patient focus first appeared on LaPorte. (authored by RSM US LLP) As margins struggle to rebound to pre-pandemic levels, strategic partnerships are expected to rise in health care this year.

52

52

Hallmark Brokers

FEBRUARY 24, 2023

Keep reading for five ways sellers can focus on positives. The first way to focus on the positives when selling your business. Read more The post As a Seller, Focus on the Positives appeared first on Hallmark Brokers. A lot goes into selling a business.

52

52

Appraisers Blog

MARCH 24, 2022

The post Hocus Pocus Magic Focus? Adjustments: Now What? So, what are these methods and techniques? We’re told to “support” our adjustments. We hear words like “prove” your adjustments. appeared on Appraisers Blogs.

Appraisal 75

Appraisal Marketability 75

Law 360 M&A

MAY 26, 2023

billion takeover of Activision Blizzard will focus on the makeup of the cloud gaming market and its commitment to keep providing games to rivals, according to a summary published Friday. Microsoft's appeal of an order from Britain's competition enforcer blocking its planned $68.7

Marketability 74

Marketability 74

Audit Board

NOVEMBER 16, 2023

Unfortunately, as AuditBoard’s 2024 Focus on the Future survey of more than 450 internal audit leaders found, many internal audit departments seem complacent or even overconfident in the face of permacrisis. Each year, Focus on the Future takes a fresh look at the leading risks commanding internal audit’s attention.

Technology 52

Technology Compliance 52

Benzinga

JUNE 27, 2022

The primary focus of the acquisition is on Epizyme's lead medicine, Tazverik (tazemetostat), a chemotherapy-free EZH2 inhibitor, which was granted FDA Accelerated Approval in 2020. Ipsen SA (OTC: IPSEY ) has agreed to acquire Epizyme Inc (NASDAQ: EPZM ) at $1.45 The deal is expected to close by Q3.

97

97

Rhythm Systems

NOVEMBER 10, 2023

This execution alignment challenge is the focus of Chapter 5 of Rhythm: How to Achieve Breakthrough Execution and Accelerate Growth. You’ve identified your critical strategic winning moves. How do you translate those into detailed, actionable plans across your organization?

52

52

Law 360 M&A

FEBRUARY 27, 2024

Higher consumer prices and reduced choice are no longer the only reasons the Federal Trade Commission will challenge mergers after the agency contested Kroger's planned $24.6 billion purchase of Albertsons based in part, for the first time ever, on allegations the deal will reduce competition for employees.

105

105

Benzinga

JANUARY 22, 2024

This divestiture aligns with Coherus’ strategic focus on oncology, and includes Coherus’ Cimerli biologics license application, ophthalmology sales and select field reimbursement teams, Cimerli product inventory on hand, and access to proprietary commercial software. “Since entering.

Equity 52

Equity 52

Benzinga

JANUARY 8, 2024

Cytokinetics Inc (NASDAQ: CYTK ) shares are trading higher after a report on potential takeover talks with Novartis AG (NYSE: NVS ). The Wall Street Journal noted that Novartis is nearing the final stages of acquiring Cytokinetics, a company focused on developing heart disease drugs. Also Read: Full story available on Benzinga.com

Equity 52

Equity Marketability 52

Benzinga

NOVEMBER 1, 2023

Cytokinetics Inc (NASDAQ: CYTK ), a late-stage biotech company focused on cardiovascular treatments, is reportedly exploring potential takeover options as it has garnered interest from at least one major pharmaceutical company in recent months. While the company has not disclosed any specifics, it is currently assessing its next course of action.

52

52

Benzinga

NOVEMBER 8, 2022

Avenue Therapeutics Inc (NASDAQ: ATXI ) acquired Baergic Bio Inc pursuant to the previously disclosed Share Contribution Agreement with its parent company, Fortress Biotech Inc (NASDAQ: FBIO ). Founded in December 2019, Baergic Bio focuses on developing a pharmaceutical product for CNS disorders. Full story available on Benzinga.com.

97

97

Benzinga

APRIL 11, 2024

The combined company plans to focus on advancing TNT119, an anti-CD19 antibody designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. Eliem Therapeutics Inc (NASDAQ: ELYM ) has agreed to acquire Tenet Medicines Inc. ,

Finance 52

Finance 52

Mckinsey and Company

OCTOBER 10, 2022

By focusing on specific scientific and operational pain points and fully integrating AI into research workflows, biopharma companies can deliver greater patient impact and significant value.

81

81

Rhythm Systems

AUGUST 30, 2022

It’s time to slow down and develop a world-class team execution plan for next year. When we don’t slow down to plan our execution, our teams don't end up being focused on the right things, leading to mistakes and rework, and ultimately smacking our profit with a 2-by-4! How strong is your execution this year?

90

90

Mckinsey and Company

JUNE 6, 2022

Funding for logistics startups almost doubled in 2021—here’s where investors are focusing.

121

121

Benzinga

JANUARY 17, 2023

Calyxt Inc (NASDAQ: CLXT ) has agreed to merge with Cibus in an all-stock transaction to create a company focused on agriculture-based gene editing and establish facilities for trait development and next-generation plant breeding. Productivity Traits : Key basis of competition in the "seed and trait" business.

98

98

Law 360 M&A

FEBRUARY 27, 2024

Macy's announced a plan Tuesday to close 150 stores, add new luxury-focused locations and monetize at least $600 million worth of its assets as it faces a proxy fight from activist investors that offered $5.8 billion for the company last month.

40

40

Gross Mendelsohn

AUGUST 24, 2022

With a passion for serving child-focused nonprofits, Lisa Johnson’s enthusiasm for helping those organizations — both here at Gross Mendelsohn and in volunteer roles — is absolutely contagious.

78

78

Avanade

OCTOBER 5, 2023

Here are some of the more common pitfalls an organization is likely to experience when making the transition from project-focused based delivery methodologies to a product model.

52

52

Audit Board

SEPTEMBER 28, 2023

Since 2016, the European Confederation of Institutes of Internal Auditing’s (ECIIA’s) annual Risk in Focus report has sought to help Chief Audit Executives (CAEs) understand how their peers view today’s risk landscape as they prepare their forthcoming audit plans for the year ahead.

Marketability 52

Marketability Market Risk Technology 52

Benzinga

DECEMBER 18, 2023

First Wave BioPharma Inc (NASDAQ: FWBI ) has signed a non-binding term sheet to acquire ImmunogenX in an all-stock transaction with the combined company focused on advancing a pipeline for gastrointestinal (GI) diseases.

52

52

Financial Times M&A

MAY 12, 2024

New leaders say steady returns sector offers provide best fit for ‘permanent capital’ of Reimann family

85

85

Benzinga

NOVEMBER 16, 2023

The combined company will focus on advancing Q32 Bio's wholly-owned clinical development candidates for autoimmune and inflammatory diseases. Q32 Bio Inc and Homology Medicines Inc (NASDAQ: FIXX ) have entered into a definitive merger agreement to combine the companies in an all-stock transaction.

Equity 52

Equity Marketability 52

Benzinga

MAY 13, 2024

Closing is expected to occur in the third quarter and is subject to regulatory approval and other customary closing conditions. The CoverFlexx Group manufactures and sells coatings for automotive refinish and aftermarket applications, focused on economy customers in North America.

Technology 45

Technology 45